TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells
Year: 2019
Type: preprint
Abstract: The epigenetic regulator TET2 is frequently mutated in hematological diseases. Mutations have been shown to arise in hematopoietic stem cells early in disease development and lead to altered DNA methylation landscapes and an increased risk of hematopoietic malignancy. Here, we show by genome-wide mapping of TET2 binding sites in different cell types that TET2 localizes to regions of open chromatin and cell-type–specific enhancers. We find that deletion of Tet2 in native hematopoiesis as well as fully transformed acute myeloid leukemia (AML) results in changes in transcription factor (TF) activity within these regions, and we provide evidence that loss of TET2 leads to attenuation of chromatin binding of members of the basic helix–loop–helix (bHLH) TF family. Together, these findings demonstrate that TET2 activity shapes the local chromatin environment at enhancers to facilitate TF binding and provides an example of how epigenetic dysregulation can affect gene expression patterns and drive disease development.
Source: Genome Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: Kræftens Bekæmpelse, Sundhed og Sygdom, Det Frie Forskningsråd, Cancer Research UK, National Research Foundation, Danmarks Grundforskningsfond, Novo Nordisk, Novo Nordisk Fonden, National Institutes of Health, Horizon 2020 Framework Programme, Medical Research Council, European Research Council, Japan Society for the Promotion of Science, National Cancer Institute
OpenAlex ID: W2952280017
